SCHEMBL314041

SCHEMBL314041

Cc1cccc(-c2nnc3n2-c2cc(Cl)ccc2NCC3C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 6/20 0.40
TNKS O95271 4/20 0.40
TGFBR1 P36897 2/20 0.34
BRD4 O60885 2/20 0.34
TACR3 P29371 3/20 0.34
KCNH2 Q12809 2/20 0.33
MAPK1 P28482 1/20 0.33
ERG P11308 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
P2RX7 Q99572 2/20 0.32
AVPR2 P30518 1/20 0.32
OXTR P30559 1/20 0.32
GRM5 P41594 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
TACR2 P21452 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314043 1.00 TNKS2 (0.40) TNKS2TNKSTGFBR1BRD4TACR3
SCHEMBL314042 1.00 TNKS2 (0.40) TNKS2TNKSTGFBR1BRD4TACR3
SCHEMBL314133 0.92 TNKS2 (0.40) TNKS2TNKSTGFBR1BRD4TACR3
SCHEMBL314365 0.92 TNKS2 (0.40) TNKS2TNKSTGFBR1BRD4TACR3
SCHEMBL314713 0.92 TNKS2 (0.40) TNKS2TNKSTGFBR1BRD4TACR3
Trifluoroacetic Acid SCHEMBL314788 0.91 TNKS2 (0.42) TNKS2TNKSTACR3KCNH2ERG
SCHEMBL314869 0.87 TNKS2 (0.38) TNKS2TNKSTGFBR1TACR3KCNH2
SCHEMBL314870 0.87 TNKS2 (0.38) TNKS2TNKSTGFBR1TACR3KCNH2
SCHEMBL314626 0.87 TNKS2 (0.38) TNKS2TNKSTGFBR1TACR3KCNH2
SCHEMBL314039 0.86 TNKS2 (0.41) TNKS2TNKSTGFBR1TACR3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 TNKS2 630/4885TNKS 534/4885TGFBR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.